Health Canada grants priority review status to trifluridine and tipiracil for refractory metastatic colorectal cancer
Oct 20 (Reuters) - Otsuka Holdings Co Ltd <4578.T>:Taiho Pharma Canada - Health Canada accepted for review new drug submission for trifluridine, tipiracil,NDS granted priority review status.Taiho Pharma Canada - Health Canada's review of NDS under priority review is expected to be completed in early 2018.
Latest Developments forOtsuka Holdings Co Ltd
- Health Canada Approves Otsuka & Lundbeck's REXULTI As Adjunctive Treatment Of Major Depressive Disorder
- Otsuka Holdings unit completes acquisition of U.S.-based firm Visterra
- Astex Pharmaceuticals And Otsuka Announce Results Of The Phase 3 Astral-1 Study Of Guadecitabine In Treatment-Naïve AML Patients Ineligible To Receive Intense Induction Chemotherapy
- Otsuka Holdings unit to fully acquire U.S.-based firm Visterra via unit for $430 mln